An allyl group was attached to 3-keto function of ketolides in the presence of allyl bromide and KOtBu. Consequently, the Heck reaction of the resulting 2, 3-dehydro-3-O-allyl-10, 11-anhydroclarithromycin derivatives, in the presence of palladium (II) acetate and tri(o-tolyl)phosphine, afforded a 3-O-(3-aryl-E-prop-2-enyl) sidechain, not the previously reported 3-O-(3-aryl-Z-prop-1-enyl) sidechain. The results suggested that some steric factors in b-hydrogen elimination might regulate the isomerization. The activity of 2, 3-dehydro-3-O-(3-aryl-E-prop-2-enyl)-10, 11-anhydroclarithromycin derivatives was low.
INTRODUCTION
Clarithromycin, one of the semi-synthetic analogs of erythromycin A, has good acid stability in the stomach because of the incorporation of 6-OMe blocking the degradation process that involved original 6-OH and 9-keto. 1 Recently, 3-keto derivatives of clarithromycin, termed ketolides, have been developed to combat the growing prevalence of MLS B resistance. 2 Ketolides, the third-generation erythromycin derivatives, are represented by telithromycin (HMR3647), 3 cethromycin (ABT-773) 4 and TE-802 5 (Figure 1 ).
The success of ketolides disproved the long held belief that 3-Ocladinose was essential moiety for the antibacterial activity. In addition to ketolides, other macrolides with various substituents at C-3 instead of cladinose have also been designed and investigated over the past decade, such as acylide, 6 3, 6-bicyclolide (Figure 2 ), 7 2, 3-anhydrolide, 8 2, 3-enol ether, 9 3-deoxy, 10 3-O-phenyl ether, 11 3, 6-ketal 12 and 3, 6-ether. 13 In our search for novel erythromycin derivatives, we previously reported some alkylides (Figure 2 ) with improved activity against erythromycin-resistant pathogens. 14 We speculated alkylides, characterized by 3-O-ether bond, might have a profile of higher acid stability and enzyme resistance compared with acylides. 6 More importantly, an allyl group could easily be transformed into other functional groups. 15 For this reason, we synthesized the alkylides to explore their structureactivity relationship. Consequently, we found that Heck isomerization occurred in the presence of palladium (II) acetate and tri(o-tolyl)phosphine, which led to a 3-O-(3-aryl-Z-prop-1-enyl) sidechain, 14 which involved an allylic double-bond isomerization and concomitant configuration isomerization. In this study, we report further modification of the configuration of the linkers at 3-OH, as well as the skeleton of macrolides.
RESULTS AND DISCUSSION
3-O-(3-aryl-E-prop-2-enyl) clarithromycin derivatives were prepared by a multi-step synthesis, as illustrated in Scheme 1. Starting material 3-OH clarithromycin was produced by the acidic hydrolysis of commercially available clarithromycin. 2 Without the addition of a base such as triethylamine or K 2 CO 3 , the 2¢-acetate 1 (see ref.
2) was smoothly obtained by treatment of 3-OH-clarithromycin with acetic anhydride, as attributed to the catalytic function of neighboring 3¢-tertiary amino group. Next, the 11, 12-carbonate 2 was easily obtained by the BTC (bis(trichloromethyl)carbonate) method reported by You. 16 An initial attempt 14 to convert 2 to the 3-O-allyl counterpart failed in the presence of allyl bromide and KOtBu. The major product in the resulting mixture was identified as 10, 11-anhydro-3-OH-6-O-methylerythromycin A 3 after methanolysis. In contrast, the 3-keto 4 resulting from the Corey-Kim oxidation 17 of 2, successfully yielded corresponding the 2, 3-dehydro-3-O-allyl analog 5 in the presence of allyl bromide and KOtBu. A similar phenomenon was reported by Denis concerning four-atom-length and five-atom-length alkoxy linkers using NaH as the base. 9 Meanwhile, the 11, 12-carbonate underwent smooth elimination in the presence of KOtBu and was converted to the 10, 11-olefin. Thus, in addition to previously reported DBU, 16 KOtBu seemed to be effective in decarboxylation, but it is noted that the elimination of the 11, 12-carbonate under the same reaction condition would be hampered when the 9-keto was converted to an oxime ether. 14 After the introduction of the allyl group, a three-atom-length allylic linker was formed to serve for further modification. In the presence of palladium (II) acetate and tri(o-tolyl) phosphine, an aryl group was attached to the allyl group. Interestingly, the Heck reaction yielded the expected 3-O-(3-aryl-E-prop-2-enyl) derivatives 6 without Heck isomerization. According to the crystal structure of the alkylide, 14 we speculated that spatially neighboring 5-O-desosamine probably led to Heck isomerization of C-3 sidechain, whereas the introduction of 2, 3-olefin may change the conformation of skeleton of macrolide, and thus make the 3-O-allyl functional group be farther away from originally spatially neighboring 5-O-desosamine. 14 However, this hypothesis would require further studies to be fully assessed. Finally, the target compound 7 was obtained by methanolysis. The selected aromatic rings included 3-quinolyl (a), 5-indolyl (b), 3-pyridyl (c) and 4-isoquinolyl (d) group.
The in vitro antibacterial activity of 7a-7d was assessed against erythromycin-susceptible and erythromycin-resistant bacteria including Staphylococcus aureus and Streptococcus pneumoniae. Data are tabulated in Table 1 as the MIC, which was determined by the broth microdilution method, as recommended by the Clinical and Laboratory Standards Institute. 18 The MIC test indicated that 7a-7d were generally inactive to the selected pathogens, especially for S. pneumoniae. Only 7d (4-isoquinolyl) had a slightly higher activity against erythromycin-resistant S. aureus than the reference compound, clarithromycin. This antibacterial evaluation reconfirmed that position 2 of the skeleton of macrolides needs to remain tetrahedral to retain good activity. 9 On the other hand, the formation of 10,11-olefin also proved to have negative effects on the activity of macrolides, but further transformation of 10, 11-olefin to 11, 12-carbamate could improve the activity dramatically. 8 Nevertheless, the aryl sidechain appended at C-3 could improve the activity of macrolides, because compound 7 showed much higher activity against both susceptible and resistant strains compared with 2, 3; 10, 11-dianhydroclarithromycin, a 3-dealkyloxy version of 7 with abolished activity (all MICs4100 mg ml À1 ). 8 In conclusion, a series of 2, 3-dehydro-3-O-(3-aryl-E-prop-2-enyl)-10, 11-anhydroclarithromycin derivatives were synthesized via the allylation of the 3-keto precursor followed by Heck reaction. As the structure of 2, 3-olefin and 10, 11-olefin may contribute much to low activity, further efforts would be devoted to the synthesis of 3-O-(3-aryl-E-prop-2-enyl) clarithromycin derivatives without 2, 3-olefin and 10, 11-olefin to search for better efficacy against resistant bacteria.
EXPERIMENTAL PROCEDURE
All solvents and reagents were obtained from commercial sources and used without further purification unless otherwise noted. 1 H and 13 C NMR spectra were recorded in CDCl 3 on a Bruker ARX 400 MHz, 600 MHz (Bruker, Switzerland) with tetramethylsilane (TMS) as an internal standard. The assignments of 7e were made based on 1 H-1 H COSY. HRMS were obtained with Bruker Apex IV FTMS (Bruker, USA). Column chromatography was performed with silica gel (Qingdao Haiyang, Qingdao, China; 200-300 mesh grade). NH 3 H 2 O refers to 25% aqueous ammonium hydroxide.
3-OH-6-O-CH 3 -erythromycin A
To a stirred solution, 80 ml of water and 4 ml of 36% aqueous HCl was added followed by 10 g of clarithromycin. The reaction was stirred at room temperature for 2 h, and then was adjusted to pH 9 with 25% aqueous NH 3 . The precipitate was collected by filtration, and washed with cold water to afford 6.8 g of 3-OH-clarithromycin 2 (86.2%). HRMS (ESI) (M+H) + m/z 590.3901, calculated for C 30 H 56 NO 10 590.3898.
2¢-O-Ac-3-OH-6-O-CH 3 -erythromycin A (1)
A solution of 3-OH-clarithromycin (5.4 g, 9.2 mmol) in CH 2 Cl 2 (50 ml) was treated with acetic anhydride (2.0 ml, 20.7 mmol) at room temperature for 1 h. The reaction mixture was washed with saturated NaHCO 3 , water and brine. The organic layer was dried over MgSO 4 
2¢-O-Ac-3-OH-6-O-CH 3 -11, 12-carbonate erythromycin A (2)
To a solution of 1 (10.2 g, 16.2 mmol) in CH 2 Cl 2 (200 ml), pyridine (15.6 ml, 193.8 mmol) was added and then a solution of BTC (bis(trichloromethyl)carbonate) (9.6 g, 32.3 mmol) in CH 2 Cl 2 (80 ml) was dropped over 2 h. The reaction mixture was stirred at À5 1C for 7 h. Then 200 ml of brine was added dropwise to the reaction mixture. The organic layer was washed with saturated NaHCO 3 , water and brine and then dried over MgSO 4 , filtrated and concentrated to yield 2 (see ref. 16) (10.0 g, 94.2%).
3-OH-6-O-CH 3 -10,11-anhydroerythromycin A (3)
The procedure described as below was originally designed to prepare 3-Oallyl-6-O-methylerythromycin 11, 12-carbonate, but unexpected results were observed.
To a solution of 2 (1.0 g, 1.5 mmol) in 10 ml of DMSO and 10 ml of THF, allyl bromide (0.25 ml, 3.0 mmol) and KOtBu (0.5 g, 3.0 mmol) was added. The mixture was stirred for 30 min at 0 1C, then quenched with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over MgSO 4 , filtrated and concentrated. The crude product was heated to reflux in MeOH, and then the solution was concentrated. The residue was 
To a solution of 4 (2.0 g, 3.0 mmol) in 20 ml of DMSO and 20 ml of THF, allyl bromide (0.51 ml, 6.0 mmol) and KOtBu (1.0 g, 6.0 mmol) was added. The mixture was stirred for 30 min at 0 1C, then quenched with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over MgSO 4 , filtrated and concentrated to yield 5 (1.8 g, 90.5%). The structure of 5 was confirmed by the H-H COSY anal of 7e.
2, 3-Dehydro-3-O-allyl-6-O-CH 3 -10, 11-anhydroerythromycin A (7e)
The product 5 was heated to reflux in MeOH at 65 1C for 3 h. After the solvent was evaporated in vacuo, the residue was purified by column chromatography on silica gel (15:0. 
2, 3-Dehydro-3-O-[3-(4-isoquinolyl)-E-2-propenyl]-6-O-CH 3 -10, 11-anhydroerythromycin A (7d)
Following the procedure for 7a, 6d (257 mg) was prepared as a yellow solid from 5 (0.9 g), and then deacetylated to give pure 7d (117 mg, 11.5% in two steps 
